GPC6 and breast carcinoma: Based on the analysis of 3951 breast cancer patients from a public database, Grillo et al. suggested that glypicans could serve as prognostic biomarkers for breast cancer patients [27] as they found that low GPC6 was correlated with longer survival time [27], which is consistent with our findings that the low-risk group had lower GPC6 expression.